Allergic Reaction Clinical Trial
Official title:
Quercus Ilex and Quercus Robur Allergen Extracts. Determination of the in Vivo Allergenic Potency in Histamine Equivalent Units (HEP).
The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
The trial will consist of a single visit, in which the following procedures will be carried out: - Demographic data. - Clinical history. - Inclusion/exclusion criteria. - General examination. - Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control). - Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed. - Evaluation of adverse events. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04058743 -
Nickel Sensitivity
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Active, not recruiting |
NCT05605795 -
Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
|
||
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Completed |
NCT04510376 -
Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method
|
N/A | |
Completed |
NCT05185479 -
Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
|
||
Recruiting |
NCT05185362 -
Epidemiology of Pecan Nut Allergy
|
||
Completed |
NCT03525496 -
Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
|
||
Completed |
NCT03489694 -
Repeatability and Reproducibility of Skin Test Endpoint Titration
|
||
Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
Enrolling by invitation |
NCT05670756 -
Preoperative Survey to Evaluate Patient Allergy
|
||
Recruiting |
NCT05462444 -
Development of Personalized Balanced Nutrition Concept Through an IT Platform
|
||
Not yet recruiting |
NCT05284253 -
Is There an Allergy to Pure Metallic Gold Microparticles?
|
N/A | |
Completed |
NCT03157505 -
Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01436617 -
Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
|
Phase 2 | |
Not yet recruiting |
NCT05533385 -
Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.
|
N/A | |
Recruiting |
NCT06011603 -
Prineo Sensitivity Dressing Study
|
Phase 4 | |
Completed |
NCT04761822 -
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
|
Phase 2 | |
Recruiting |
NCT05367531 -
Assessment of Injectable Medication Platforms
|
N/A |